Continuous glucose monitoring (CGM) represents one of the most commercially robust sectors within medical technology, transitioning diabetes management from episodic capillary blood testing to continuous, actionable glycemic trend analysis. Despite widespread adoption among insulin-dependent populations, conventional CGM systems remain tethered to subcutaneous filament architectures that penetrate several millimeters into the skin, introducing tissue trauma, biofouling and ma

Europe and the UK are overhauling healthcare AI oversight, shifting from static approvals to continuous lifecycle monitoring to ease compliance burdens under the EU AI Act and Medical Device Regulations. Concurrently, AI captured 48% of European health venture capital in 2026, driving major funding rounds and acquisitions like GE HealthCare's $945 million deal for SOFIE Biosciences. Meanwhile, cross-border clinical pilots, sovereign compute initiatives, and digital twins are

The European healthcare sector has arrived at a structural inflection point in clinical documentation and ambient intelligence. Ambient Voice Technology (AVT), which initially commanded premium software valuations by converting clinician patient dialogue into structured clinical summaries, is succumbing to rapid technological commoditisation. Foundational acoustic modelling and large language model (LLM) summarisation capabilities have matured into accessible utilities, erodi

The consumer healthcare industry is experiencing an operational and commercial transformation. Over the counter (OTC) medicines, oral care, and nutritional wellness brands, historically managed as downstream commercial offshoots of research-and-development-driven pharmaceutical conglomerates, are decoupling from corporate biopharmaceutical parents. Operating as independent, market responsive commercial entities, these businesses face fundamentally restructured corporate manda